Advanced Cell Technology, Inc. (ACTC) Receives Patent for New Method of Generating Hemangioblast Cells from Human Stem Cells
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received a patent for technology that can generate and expand hemangioblast cells from human embryonic stem cells. ACT says this technology will use stem cells for the creation of renewable sources of transfuseable blood and platelets to meet the demand for donated blood that can repair damage caused by diseases including diabetes, heart disease, osteoarthritis and multiple sclerosis. ACT has an exclusive license for the commercialization of the technology through a joint venture with South Korean biotechnology company CHA Bio & Diostech Co.…